Pharmaceutical formulation including a resinate and an aversive agent

• US 7,655,256 B2
• Filed: 10/06/2003
• Issued: 02/02/2010
• Est. Priority Date: 09/17/2001
• Status: Active Grant

• Current Assignee: Rohm and Haas Company (Dow, Inc.)
• Original Assignee: Rohm and Haas Company (Dow, Inc.)
• Inventors: Hughes, Lyn
• Primary Examiner(s): Azpuru; Carlos A
• Application Number:
  US10/679,785
• Publication Number:
  US 20040126324A1
• Time in Patent Office: 2,311 Days
• Field of Search: None
• US Class Current: 424/454
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/36 Opioid-abuse

Abstract

The present invention provides a pharmaceutical that includes, in combination, a resinate and an aversive agent. The resinate includes an ion exchange resin and an drug. The drug is a controlled substance. In variants of the invention, both the aversive agent and the controlled substance are loaded onto the ion exchange resin; the aversive agent is loaded onto the ion exchange resin, and the controlled substance is not loaded onto the ion exchange resin; the controlled substance is loaded onto the ion exchange resin, and the aversive agent is not loaded onto the ion exchange resin; or, the controlled substance is loaded onto a first ion exchange resin, and the aversive agent is loaded onto an ion exchange resin different from the first ion exchange resin.

Claims

1. A pharmaceutical comprising, in combination, a resinate and an aversive agent wherein said resinate comprises an ion exchange resin and a drug.

2. The pharmaceutical of claim 1 in which said aversive agent is selected from the group consisting of capsaicin, derivatives of capsaicin, and mixtures thereof.

3. The pharmaceutical of claim 1 in which said drug is a controlled substance.

4. The pharmaceutical of claim 3 in which both said aversive agent and said controlled substance are loaded onto said ion exchange resin.

5. The pharmaceutical of claim 3 in which said aversive agent is loaded onto said ion exchange resin, and said controlled substance is not loaded onto said ion exchange resin.

6. The pharmaceutical of claim 3 in which said controlled substance is loaded onto said ion exchange resin, and said aversive agent is not loaded onto said ion exchange resin.

7. The pharmaceutical of claim 3 in which said controlled substance is loaded onto a first ion exchange resin, and said aversive agent is loaded onto an ion exchange resin different from said first ion exchange resin.

8. The pharmaceutical of claim 1 in the form of a tablet or capsule.